Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Open, Positive-controlled Two-stage Phase II Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects

NCT05602129 is registered in ClinicalTrials.gov with Haisco Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT05602129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05602129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Open, Positive-controlled Two-stage Phase II Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects
Lead sponsor
Haisco Pharmaceutical Group Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2022
Completion date
October 31, 2023
Enrollment
156 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal replacement therapy